Generated: April 27, 2017
|Title:||Pharmaceutical delivery system|
|Abstract:||A composition for use in an aqueous environment which .[.comprise.]. .Iadd.comprises .Iaddend.a formulation containing a water-soluble pharmaceutically beneficial agent, a water-insoluble, water-permeable film coating surrounding the formulation, and particulate, water-soluble, pore-forming material dispersed within the film coating. The questions raised in reexamination request No. 90/001,344, filed Oct. 5, 1987, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).|
|Inventor(s):||Baker; Richard W. (Palo Alto, CA), Brooke; James W. (Sisters, OR)|
|Assignee:||Burroughs Wellcome Co. (Research Triangle Park, NC)|
1. A tablet comprising a core containing the admixture of a water-soluble medicine and a water-soluble osmotic enhancing agent in an amount by weight about equal to or greater than
the weight of the medicine, said core having a water-insoluble, water-permeable coating surrounding said core, said coating-containing particulate, water-soluble, pore-forming material dispersed therein..]. .[.2. The tablet of claim 1 in which the
osmotic enhancing agent is a pharmaceutically acceptable water-soluble sugar or salt..]. .[.3. The tablet of claim 2 in which the pore forming material dispersed in the coating is a pharmaceutically acceptable water-soluble sugar or salt..]. .[.4. The
tablet of claim 1 in which the osmotic enhancing agent and the pore-forming material are both lactose..]. .[.5. A composition comprising a core containing the admixture of a water-soluble medicine and a water-soluble osmotic enhancing agent in an amount
by weight about equal to or greater than the weight of the medicine, said core having a water-insoluble, water-permeable coating surrounding said core, said coating containing particulate, water-soluble pore-forming material dispersed therein and an
agent to increase the water|
permeability of the coating dispersed therein..]. .[.6. The composition of claim 5 wherein the water permeability increasing agent is polyethylene
glycol..]. .Iadd.7. A controlled release composition for oral administration comprising bupropion hydrochloride in solid sustained release pharmaceutical carrier, said composition releasing about 10% to 45% of bupropion hydrochloride within two hours, releasing about 25% to 70% of bupropion hydrochloride within four hours, and releasing about 40% to 90% of bupropion hydrochloride within six hours, as measured in simulated gastric buffer with a pH of 1.5 at 37.degree. C. .Iaddend.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.